Compile Data Set for Download or QSAR

Found 3 hits of ic50 for monomerid = 50101777   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kJ/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101777 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-({5-[2-(carb...) Show SMILES NC(=N)NC(=O)CCc1ccc(s1)C(=O)NC[C@H](NC(=O)OCc1ccccc1)C(O)=O Show InChI InChI=1S/C20H23N5O6S/c21-19(22)25-16(26)9-7-13-6-8-15(32-13)17(27)23-10-14(18(28)29)24-20(30)31-11-12-4-2-1-3-5-12/h1-6,8,14H,7,9-11H2,(H,23,27)(H,24,30)(H,28,29)(H4,21,22,25,26)/t14-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	39	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of human 293 cell attachment to immobilized vitronectin receptor(Vn/293) by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-V/beta-3 (Homo sapiens (Human))	BDBM50101777 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-({5-[2-(carb...) Show SMILES NC(=N)NC(=O)CCc1ccc(s1)C(=O)NC[C@H](NC(=O)OCc1ccccc1)C(O)=O Show InChI InChI=1S/C20H23N5O6S/c21-19(22)25-16(26)9-7-13-6-8-15(32-13)17(27)23-10-14(18(28)29)24-20(30)31-11-12-4-2-1-3-5-12/h1-6,8,14H,7,9-11H2,(H,23,27)(H,24,30)(H,28,29)(H4,21,22,25,26)/t14-/m0/s1	PDB UniProtKB/SwissProt antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	837	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of Kistrin to Vitronectin receptor (alpha V beta 3) by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair
Integrin alpha-IIb/beta-3 (Homo sapiens (Human))	BDBM50101777 ((2S)-2-{[(benzyloxy)carbonyl]amino}-3-({5-[2-(carb...) Show SMILES NC(=N)NC(=O)CCc1ccc(s1)C(=O)NC[C@H](NC(=O)OCc1ccccc1)C(O)=O Show InChI InChI=1S/C20H23N5O6S/c21-19(22)25-16(26)9-7-13-6-8-15(32-13)17(27)23-10-14(18(28)29)24-20(30)31-11-12-4-2-1-3-5-12/h1-6,8,14H,7,9-11H2,(H,23,27)(H,24,30)(H,28,29)(H4,21,22,25,26)/t14-/m0/s1	PDB KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Patents Similars	PubMed	n/a	n/a	2.90E+3	n/a	n/a	n/a	n/a	n/a	n/a
Aventis Pharma Deutschland GmbH Curated by ChEMBL					Assay Description Concentration required to reduce binding of fibrinogen (Fg) to alpha IIb beta3 integrin by 50%				Bioorg Med Chem Lett 11: 2011-5 (2001) BindingDB Entry DOI: 10.7270/Q2N87930
					More data for this Ligand-Target Pair